Navigation Links
Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
Date:5/11/2011

FORT WORTH, Texas, May 11, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced the introduction of OASIS® Ultra Tri-Layer Matrix, a natural extracellular matrix (ECM) material derived from three layers of porcine small intestinal submucosa (SIS). The three-layer construct of ECM was designed to incorporate increased structure into difficult-to-heal and chronic wounds.

"We are pleased to introduce OASIS® Ultra as an extension of our SIS product offerings," said Travis Baugh, President and Chief Operating Officer of Healthpoint Biotherapeutics. "The three-layer design provides healthcare professionals with an important therapeutic option for temporary ECM replacement in complex wounds where increased strength and thickness is called for as part of the treatment protocol."

SIS, the base technology for OASIS® Ultra, is among the most widely studied and published biomaterials, featured in more than 832 scientific publications.

OASIS® Ultra is indicated for the management of wounds including surgical, partial- and full-thickness, traumatic (including second degree burns), venous ulcers, chronic vascular ulcers, diabetic and pressure ulcers, and draining wounds.  The product should not be used in patients with known sensitivity to porcine material and is not indicated for use in third-degree burns.

About Healthpoint Biotherapeutics

Healthpoint Biotherapeutics is a biopharmaceutical company focused on the development and commercialization of novel, cost-effective solutions for tissue repair and healing. The company's diversified research and development strategy is presently centered around therapeutic enzymes, biologics and next-generation cell- and cell-matrix based therapies for the prevention and treatment of acute, chronic and burn-related wounds. Currently marketed products include Collagenase SANTYL® Ointment, OASIS® Wound Matrix and OASIS® Ultra Tri-Layer Matrix. Healthpoint Biotherapeutics is also committed to advancing the care and treatment of wounds through support of industry-leading continuing education from The Wound Institute®. To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com.  Healthpoint Biotherapeutics is a DFB Pharmaceuticals, Inc., affiliate company, and is based in Fort Worth, Texas. For more information, visit the company website at www.Healthpoint.com.

HEALTHPOINT, SANTYL, THE WOUND INSTITUTE and THEWOUNDINSTITUTE.COM are registered trademarks of Healthpoint, Ltd.

OASIS is a registered trademark of Cook Biotech, Inc.


'/>"/>
SOURCE Healthpoint Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Healthpoint Launches New Corporate Identity
2. Healthpoint to Present at 29th Annual J.P. Morgan Healthcare Conference
3. Healthpoint Launches Collagenase SANTYL(R) Ointment in Canada
4. HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
5. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
6. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
7. Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff
8. Oxford BioTherapeutics Licenses BioWas POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
9. CardioVascular BioTherapeutics Submits FDA Application for Fast Track Status for CVBT-141B, CVBTs Biological Treatment for Diabetes Patients
10. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
11. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ), a ... healthcare systems, today announced results for its fiscal year ... --> --> GAAP results: Revenue for ... $5.1 million or 4.1% from the third quarter of ... fourth quarter of 2014. Revenue for the year ended ...
(Date:2/4/2016)... Feb. 4, 2016 In response to the opioid ... Deputy Commissioner for Medical Products and Tobacco, along with other ... the agency,s approach to opioid medications. The plan will focus ... patients in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ensure ...
(Date:2/4/2016)... -- --> --> ... Automated External Defibrillator (AED) Market by Product (Semi-Automated External ... Hospitals, Homecare & Nursing Homes) - Forecast to 2019", ... and segments the concerned market with an analysis and ... grow to about $367.0 million by 2019, at a ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... , ... The event is being held on April 7, 2016 from 5:30 ... Over Parkinson’s will fund nearly $100,000 for research for the care and cure of ... and is the architect of this informative event to raise awareness and funds for ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe ... signed a joint enrollment and degree completion agreement. The agreement, which begins ... degrees at FHU|Dickson. , The agreement allows students to be jointly admitted ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one ... time for this weekend’s Big Game. Take the stress out of your party preparation ... your guests happy at every stage of the game. , “The key to hosting ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is ... to provide the most effective tattoo removal today, Dr. Bentkover is the only doctor ... by Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) ...
Breaking Medicine News(10 mins):